Baseline demographic and clinical characteristics (all treated patients)
Characteristic . | Patients (N = 92) . |
---|---|
Age, median (range), y | 67 (37-87) |
Male sex | 48 (52) |
Disease stage at diagnosis* | |
I | 8 (9) |
II | 12 (13) |
III | 30 (33) |
IV | 41 (45) |
Bone marrow involvement | |
Yes | 29 (32) |
No | 55 (60) |
Not reported | 8 (9) |
FLIPI score at diagnosis | |
0-1 | 8 (9) |
2 | 20 (22) |
3-5 | 38 (41) |
Not reported | 26 (28) |
Number of prior lines of therapy | |
Median (range) | 3 (2-10) |
2 | 34 (37) |
3 | 19 (21) |
≥4 | 39 (42) |
Disease status at baseline | |
Relapsed | 60 (65) |
Refractory | 32 (35) |
Progression from diagnosis to progression after first-line therapy | |
Median (95% CI), y | 2.4 (1.7-3.1) |
<2 y | 41 (45) |
≥2 y | 50 (55) |
Prior radiotherapy | 29 (32) |
Prior autologous HCT | 15 (16) |
Characteristic . | Patients (N = 92) . |
---|---|
Age, median (range), y | 67 (37-87) |
Male sex | 48 (52) |
Disease stage at diagnosis* | |
I | 8 (9) |
II | 12 (13) |
III | 30 (33) |
IV | 41 (45) |
Bone marrow involvement | |
Yes | 29 (32) |
No | 55 (60) |
Not reported | 8 (9) |
FLIPI score at diagnosis | |
0-1 | 8 (9) |
2 | 20 (22) |
3-5 | 38 (41) |
Not reported | 26 (28) |
Number of prior lines of therapy | |
Median (range) | 3 (2-10) |
2 | 34 (37) |
3 | 19 (21) |
≥4 | 39 (42) |
Disease status at baseline | |
Relapsed | 60 (65) |
Refractory | 32 (35) |
Progression from diagnosis to progression after first-line therapy | |
Median (95% CI), y | 2.4 (1.7-3.1) |
<2 y | 41 (45) |
≥2 y | 50 (55) |
Prior radiotherapy | 29 (32) |
Prior autologous HCT | 15 (16) |
Data are reported as n (%), unless noted otherwise.
FLIPI, Follicular Lymphoma International Prognostic Index.
Disease stage at diagnosis was not reported for 1 patient.